Kantonsspital St.Gallen

Indications to teriparatide treatment in patients with osteoporosis

R Rizzoli, M Kraenzlin, M A Krieg, H Mellinghoff, O Lamy & K Lippuner

abstract To prevent osteoporotic fracture occurrence, a variety of treatment regimens with different mechanisms of action is available. The antiresorptive bisphosphonate drugs are currently the most commonly prescribed agents in the management of patients with osteoporosis. The recombinant amino-terminal fragment of human parathyroid hormone (Teriparatide) is a bone anabolic agent which reduces fracture risk by increasing bone mass and improving bone microarchitecture. Teriparatide treatment reduces vertebral and non-vertebral fracture risk markedly in women and men with idiopathic osteoporosis, or with glucocorticoid-induced osteoporosis. Teriparatide should thus be considered as first line treatment for postmenopausal women and for men with severe osteoporosis.
citation Rizzoli R, Kraenzlin M, Krieg M A, mellinghoff h, Lamy O, Lippuner K. Indications to teriparatide treatment in patients with osteoporosis. Swiss Med Wkly 2011; 141:w13297.
type journal paper/review (English)
date of publishing 07-11-2011
journal title Swiss Med Wkly (141)
ISSN electronic 1424-3997
pages w13297
PubMed 22057669
DOI 10.4414/smw.2011.13297